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Abstract 
 
Chronic Obstructive Pulmonary Disease (COPD) is predicted by 2020 to be the third 
leading cause of death. Acute exacerbations of COPD (AECOPDs) are common in the 
COPD patient and particularly require hospitalization. Cigarette smoke is a major risk 
factor for the development of COPD. The gram negative bacterium Haemophilus 
influnenzae (H.i) plays a major role during exacerbations in patients with COPD.  
 
The aim of this work is to investigate the effects of a combined stimulation with 
cigarette smoke (CS) and H.i on the inflammatory response and the development of 
pulmonary emphysema in mice. This will help us to better understand the mechanisms 
that lead to the overwhelming inflammatory response in COPD exacerbations that are 
believed to be the driving force for lung destruction and overall mortality in human 
COPD patients.  
 
Mice were exposed to CS in a smoking machine for different time points of 2 weeks 
up to 6 months at 3 hours per day. After the CS exposure the mice were additionally 
challenged with nebulized lysate of inactivated H.i. We analyzed the inflammatory 
response using enzyme-linked immunosorbent assay (ELISA), Cytometric Bead Array 
(CBA), Western-Blot, real-time PCR and immunohistochemistry. To quantify the 
structural changes in the lungs we performed lung function and analyzed the lungs by 
stereological methods. 
 
Our data demonstrated that the combination of CS and H.i induced a higher release of 
Matrix metalloproteinase-12 (MMP-12) in lung homogenate, induced Chemokine 
(C-X-C motif) ligand 1 (CXCL1), also termed KC, Tumor Necrosis Faktor-α (TNF-α), 
and Interleukin-17 release into the bronchoalveolar lavage fluid (BALF). The 
immunohistological analysis indicated the enhanced expression of MMP-12 in lung 
epithelial cells. The combination of CS and H.i changed the inflammatory phenotype 
from a macrophage based inflammation to a neutrophilic inflammation, and induced 
mucus hypersecretion. We detected changes in lung function and lung architecture, 
which were dependent on the stimulation with CS and H.i. and occurred as early as 3 
months after the experiment started.  
 
In summary, our study demonstrated the interaction of CS and H.i. in a mouse model. 
It will broaden our knowledge of the molecular mechanisms that are responsible for 
the COPD development in humans. 
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Zusammenfassung 
 
Chronisch obstruktive Lungenerkrankung (COPD) wird im Jahr 2020 voraussichtlich 
weltweit die dritthäufigste Todesursache sein. Akute Exazerbationen der COPD 
(AECOPDs) kommen bei COPD-Patienten häufig vor und sind besonders häufig für 
Krankenhausaufenthalte verantwortlic. Zigarettenrauch ist der wichtige Risikofaktor 
für die Entwicklung der COPD. Das gramnegative Bakterium Haemophilus 
influnenzae (H.i) spielt eine wichtige Rolle während Exazerbationen bei Patienten mit 
COPD. 
 
Das Ziel dieser Arbeit ist es, den Einfluss der Stimulation mit Zigarettenrauch 
(cigarette smoke, CS) und H.i. auf die Entzündungsreaktion und die Entstehung des 
Lungenemphysems zu untersuchen und die Mechanismen, die zu der übermäßigen 
Entzündungsreaktion im Rahmen einer Infektexazerbation bei COPD führen, genauer 
zu verstehen. 
 
Die Mäuse wurden in einer Rauchmaschine für verschiedene Zeitintervalle von 2 
Wochen bis zu 6 Monaten für 3 Stunden pro Tag mit CS stimuliert. Nach der CS 
Exposition wurden die Mäuse zusätzlich mit vernebelten inaktivierten  H.i -Lysat 
stimuliert. Wir quantifizierten die Abgabe und Expression von 
Entzündungsmediatoren mit ELISA, Cytometric Bead Array (CBA), Western-Blot, 
real-time PCR und Immunhistochemie. Um strukturelle Veränderungen zu erkennen, 
wurden die Lungen  mit stereologischen Methoden analysiert.  
 
Unsere Daten zeigen, dass die Kombination von CS und H.i eine höhere Freisetzung 
von MMP-12 im Lungenhomogenisat und CXCL1 oder KC, TNF-α, IL-17 in der 
BALF verglichen zu den Kontrollen induziert. Die immunhistologische Analyse 
zeigte die verstärkte Expression von MMP-12 in Lungenepithelzellen. Die 
Kombination von CS und H.i verändert den entzündlichen Phänotyp von einer 
Makrophagen basierter Entzündung zu neutrophilen Entzündung, induzierte eine 
Schleim-Hypersekretion, führte zu einer schlechteren Lungenfunktion und einer 
Veränderung der Lungenstruktur bereits nach 3 Monaten. 
 
Zusammenfassend zeigt unserer Studie das systematische Zusammenspiel von CS und 
H.i im Mausmodell.  
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1. Introduction 
 
Chronic obstructive pulmonary disease (COPD) is the most common health problem 
in the world and projected to be the third leading cause of death worldwide by 2020. 
COPD ranked as the fourth leading cause of death in 2010 in Germany and the third 
place in the U.S. The health care costs of COPD in the U.S. were $42.6 billion in 
2007 and $2.1 trillion worldwide in 2010 (1-3). 
 
1.1 Chronic obstructive pulmonary disease (COPD) 
 
Chronic obstructive pulmonary disease (COPD) is defined as a chronic lung disease 
with poorly reversible airway obstruction, pulmonary and systemic inflammation, and 
pulmonary emphysema (4, 5). Airway obstruction is resulted mostly from chronic 
bronchitis induced mucus hypersecretion and air way fibrosis (6, 7).  
Pulmonary emphysema is characterized by irreversible destruction of airway 
parenchyma (8). Emphysema is a result of the tissue remodeling in air space. 
Emphysema is an important manifestation of COPD, and induced mostly by long term 
cigarette smoke. The cause of emphysema are normally accepted as 
apoptosis/proliferation of type I/II pneumocytes, proteinase/anti-proteinase imbalance 
and oxidative stress in lung (9). The patients with genetic α1-antitrypsin deficiency 
develop spontaneous emphysema (10). 
COPD patients show systemic manifestation, such as skeletal muscle weakness and 
cachexia (5). The proinflammatory cytokines TNF-α and IL-1β from the pulmonary 
and systemic inflammation may play an important role. Some study reported that 
animal administrated with TNF-α induced cachexia, anemia, and leukocytosis (11).  
Furthermore, the pulmonary and systemic inflammation induced inflammatory 
cytokines into circulation may play an important role for the comorbidities of COPD, 
such as ischemic heart dysfunction, cerebrovascular disease, arrhythmias, 
osteoporosis, lung cancer, depression and diabetes. COPD patients with important  
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comorbidities are in general older and require more medical attention. The 
comorbidities increased hospitalization, mortality, healthcare costs of COPD patients 
and worsen life quality (5, 12).  
 
 
Figure.1.1 
 
 
Figure.1.1. the extrapulmonary comorbidities of COPD.  
The systemic inflammation induced the release of proinflammatory cytokine such as, IL-6, IL-8, IL-1β 
and TNF-α into circulation, may worsen COPD and initiate comorbidities, including skeletal muscle 
weakness, ischemic heart dysfunction, cerebrovascular disease, arrhythmias, osteoporosis, lung cancer, 
depression and diabetes.   
 
 
1.1.1 Risk factors of COPD 
 
The risk factors which have been found to induce and increase COPD, are cigarette 
smoking, severe infections, occupational dust, vapors, and fumes, indoor and outdoor 
pollutants, ageing, infections and genetic factors. It is now worldwide accepted that 
10-20% of smoker are susceptible and develop clinically COPD (13). Severe  
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infections during childhood have been associated with reduced lung function and 
increased respiratory symptoms in adulthood (14). Smoking during pregnancy may 
affect fetal lung growth and therefore increase the risk of COPD. Indoor and outdoor 
air pollutants are also the important risk factors for the development of COPD. WHO 
estimates that, in countries of low and middle income, 35% of people with COPD 
developed the disorder after exposure to indoor smoke from biomass fuels (15). 
Compared to the indoor air pollutants the contribution of outdoor air pollutants to the 
development of COPD is much smaller. WHO estimates that urban air pollution 
causes 1% of COPD cases in high-income countries and 2% in nations of low and 
middle income (16). Infections have an important role in both development and 
progression of COPD. Bacterial or viral infections are normally involved in most 
COPD exacerbations (17). The deficiency of the serine protease α1 antitrypsin is the 
best known genetic factor related to COPD, which arises in 1–3% of COPD patients. 
In total, the cause of COPD is a multi-factor event (18). 
 
 
1.1.2 Cigarette Smoke in COPD 
 
The most important risk factor for COPD in the developed world is cigarette smoking. 
Active and passive cigarette smoke exposure contributes to increased respiratory 
diseases such as COPD, asthma, and lung cancer (9). Cigarette smoking induced 
about 80–90% of COPD cases in the United States (19).  
Smoking, mainly refer to Tabaco, has a long history and reported to begin at 
5000-3000 BC (20). The first study about biological effect of cigarette smoking on 
health problem was focus on the lung cancer in the late of 1920s in Germany (21). 
Tabaco contained complex chemical substances. The gas phase alone contained over 
1000 different reactive specie, and the tar phase contained also abundant reactive 
substances, such as ROS and RNS. People inhaled by puffing 45% of the total 
biomass in the burning cigarette smoke from mainstream smoke and about 55% of the 
content from side stream smoke (9).  
Introduction 
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Passive smoking, also known as side stream smoke, second-hand smoke (SHS) or 
Environmental Tobacco Smoke (ETS), is more toxic than active smoke and relates 
with elevated risk in lung cancer of non-smokers or children (19).  
Inhaled reactive species by smoking induces pulmonary and circulating inflammation. 
Cigarette smoke activates immunocells such as macrophage, neutrophil and 
lymphocytes to release the proinflammatory cytokines such as TNF-α, IL-6, IL-8 and 
IL-1β in to the lung. The recruited immunocells release more proinflammatory 
cytokines. The NF-kB signaling and extracellular signal-regulated kinase 1 and 2 
(ERK1/2) are believed to involve in this pathological process. It was reported in 
several paper that tobacco components include nicotine and N-nitrosonornicotine 
(NNN) activated NF-kB in some cell lines (22, 23). NF-kB signaling plays an 
important role in regulation of innate, adaptive immunity and inflammation (24-26). 
Various papers reported that NF-kB is involved in the pathological process of COPD 
(27, 28). CS-extract activates the NF-kB signaling in mouse lung (29). However, 
target deletion of IKK, a subunit of NF-kB, shows no effect on the regulation of 
pulmonary inflammation (30). Taken together, the role of NF-kB in pathogenesis of 
COPD and emphysema is largely unknown.  
Recent studies report that a 7nAChR dependent nicotinic anti-inflammatory pathway 
modulates the inflammatory response by vagus nerve. Lipopolysaccharide (LPS) 
stimulation in 7nAChR deficient mice induces more inflammatory response than wild 
type mice (31). Nicotinic acetylcholine receptors (nAChRs) is mainly studies in 
neurons and muscle and also associated with macrophage, which mainly regulate the 
pulmonary inflammation (32-34).These studies provide a beneficial role with cigarette 
smoking induced inflammation. However, it common accepted currently that cigarette 
smoking is harmful and the most important risk factor in COPD.  
 
 
1.1.3 Systemic inflammation in COPD 
 
Recent studies highlight the systemic inflammation including increased  
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concentrations of circulating inflammatory cytokines, chemokines, and acute phase 
proteins, or abnormalities in circulating cells during COPD (35). However, the 
mechanism including the origin of the systemic inflammation in patients with COPD 
remains poorly understood. Cigarette smoke is the most important risk factor of some 
important extrapulmonary effects. The systemic inflammation in COPD may 
contributed by tobacco. Passive smokers and smokers with only few pack-years 
suffered from systemic oxidative stress and peripheral vascular endothelial 
dysfunction (36, 37). The other possible role of tobacco smoke in COPD is the local 
pulmonary inflammatory response in systemic inflammation (38). Whether like IL-6, 
IL-8, IL-1β and TNF-α are important proinflammatory cytokines which released in 
the peripheral lung, and related to comorbid disease remains also poorly understood. 
Systemic inflammation is increased during exacerbations and induced accelerated 
impaired lung function (39, 40).  
 
 
1.1.3.1 The proinflammatory cytokines and chemokines in COPD 
 
The proinflammatory cytokines and chemokines such as IL-6, TNF-a, IL-1β, IL-8 and 
other CXC chemokines are increased in the BALF and systemic circulation of COPD 
patients and also during exacerbations (41). 
The increased level of circulating IL-6 was reported mostly in viral induced acute 
exacerbation of patients with COPD (42). Stable COPD patients have also increased 
circulating IL-6, which may be associated with skeletal muscle wasting (43), cachexia, 
inflammatory bowel diseases (IBD) (44). IL-6 is produced mainly from T 
lymphocytes, macrophage, smooth muscle cells, and partially in osteoblast. The major 
function of IL-6 is the induction of fever (45). In air space, IL-6, IL-8 and TNF-α are 
an important chemoattractant for the monocyte. 
IL-1β is an important proinflammatory cytokine, which produced mainly in activated 
macrophage. IL-1β has various cellular function such as apoptosis and proliferation. 
IL-1β also affects the central nervous system (CNS). Cachexia patients have increased  
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level of IL-1β in circulating system (46). IL-1β in airway correlates the severity of 
COPD (47). IL-1β and TNF-α mainly activate NF-κB signaling (48).  
TNF-α is also released mainly from activated macrophage and also from other cell 
type, such as neutrophil, eosinophils, NK cells and mast cells. The TNF-α is involved 
in local pulmonary and systemic inflammation (49).The main related signaling of 
TNF-α is NF-κB, MAPK pathways and death signaling. In mice the TNF-α level is 
associated with tissue remodeling in air space (50). 
CXCL8 (IL-8) is released mainly in macrophage and other cell types, such as 
epithelial cells, endothelial cells and smooth muscle cells. IL-8 can be produced in all 
cells which contain the toll-like receptors. The major function of IL-8 is as 
chemoattractant of neutrophil. Circulating IL-8 concentration is associated with 
muscle wasting (51). 
 
 
1.1.3.2 Inflammatory cells in COPD 
 
Smoker has increased amount of pulmonary neutrophils, lymphocytes and 
macrophages (52). The circulating leukocytes show also abnormal function in COPD 
patients. The specific roles of each circulating cells in COPD patients remain to be 
determined.  
Neutrophil is the major cell type in innate immunity. Neutrophil releases the 
neutrophil elastase, which is believed to play an important role in tissue remodeling in 
lung. The inhibitor of neutrophil elastase is α1-antitrypsin.α1-antitrypsin deficiency 
induces spontaneous emphysema. Neutrophil release also various proinflammatory 
cytokines, such as, IL-8, IFNγ, C3a, C5a, and LB4, the chemoattractant of neutrophil 
is IL-8. 
COPD patients have not increased neutrophil in circulation and pulmonary air space. 
Some studies report that impaired lung function of COPD patients is related with 
neutrophil (53).  
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Phagocytosis is the major function of airway macrophages. Alveolar macrophages 
from smokers show decreased phagocytosis of bacteria, such as Haemophilus 
influenzae and S. pneumoniae, which colonize the lower airways of COPD patients. 
Monocyte derived macrophages from COPD patients showed a decreased phagocytic 
activity of S.pneumoniae and H.influenzae when compared to smokers or 
non-smokers. COPD patients showed a decreased phagocytic activity of 
S.pneumoniae and H.influenzae when compared to smokers or non-smokers. Some 
researchers suspect that it might be due to the defect of phagocytic machinery which 
is essential for the bacteria uptake. It may also because of the defect of innate 
immunity against bacteria (54). The reason of the defected innate immunity may be an 
intrinsic defect in monocytes, which can induce the defect of macrophages. 
The MMP12 are mainly released from macrophage, which play an important role 
tissue remodeling in lung (55). 
Some other studies indicate that the amount of B-lymphocytes in COPD patients is 
increased, whereas no change in total T-cell population is detected (56, 57). Peripheral 
T lymphocytes from COPD patients have an increased apoptosis level, which 
accompanies the increased expression level of TNF-α and TGF-b (58). One study 
reported that CD8+ cells are increased, which might induce the increased apoptosis 
(59). Normal smokers, but not COPD patients, show increased circulating CD4+ 
T-cells (60). In the lung of COPD patients the cytotoxic and phagocytic function of 
natural killer cells are decreased (61, 62). 
 
 
1.1.4 Molecular and cellular mechanisms of COPD 
 
Recently, the cellular and molecular mechanisms of COPD have been extensively 
explored. The accumulation of alveolar macrophages, neutrophils and T-lymphocytes 
in air space of COPD patients was confirmed. Various lipids, cytokines, chemokines, 
growth factors and other inflammatory mediators are released. The increased 
oxidative stress and the activation of several elastolytic enzymes, such as serine  
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proteases, cathepsins and matrix metalloproteinases, amplify the inflammation. 
Macrophages play an important role in COPD, which are activated, for example, by 
cigarette smoke. Macrophages are an important source of inflammatory mediators and 
provide a cellular mechanism which links smoking with inflammation in COPD. 
Some cellular mechanisms have been intensively studied. A short summary is shown 
in Figure 1-2. Macrophages release IL-8, GRO-a, leukotriene B4 (LTB4) in order to 
activate neutrophils via CXCR2 receptor. Alveolar destruction is possible caused by 
neutrophil secreted serine proteases, including neutrophil elastase (NE), proteinase-3, 
MMP-8 and MMP-9 (63). These serine proteases stimulate also mucus secretion. It 
was observed that neutrophil recruited to the airways and parenchyma and adhered to 
endothelial cells, E-selectin is upregulated from endothelial cells in COPD patients 
(64). Monocytes will be stimulated through macrophage chemotactic protein-1 
(MCP-1), (growth-related oncoprotein alpha (GRO-a) and CXC chemokines via 
CXCR2 receptor. The chemokines interferon-γ inducible protein 10 (IP-10) are 
released from macrophages and activate CD8+ cells by CXCR3 receptor. 
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Figure.1.2 
 
 
Figure.1.2. Systemic inflammation of chronic obstructive pulmonary disease (COPD) (4).  
Cigarette smoke mainly induces inflammatory response in macrophage, neutrophil, and lymphocyte in 
lung. Macrophages release inflammatory cytokines such as TNF-α, IL-8, growth-related oncogene-α, 
MCP-1 and IP-10. Neutrophils are attracted by IL-8, GRO-α and leukotriene B4 (LTB4), monocytes 
attracted by macrophage chemotactic protein-1 (MCP-1), and CD8+ lymphocytes attracted by 
interferon-c inducible protein (IP-10), monokine-induced interferon-c (Mig) and interferon-inducible 
T-cell a-chemoattractant (I-TAC). Proteolytic enzymes including matrix metalloproteinases (MMP) and 
cysteine proteinase such as cathepsins induced ECM breakdown. 
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Some other cells, such as eosinophils, dendritic cells and epithelial cells may be 
important sources of inflammatory mediators and proteases in COPD (65-67). 
The alveolar macrophages from COPD patients release most of inflammatory 
mediators. The transcription factor NF-kB is activated in alveolar macrophage, and is 
believed to regulate the expression of inflammatory mediator from COPD patients, 
particularly during exacerbation (68, 69). 
NF-kB signal pathway plays an important role in COPD. NF-kB acts as a central 
transcription factor by inflammatory, and also a key molecule involved in cell survival 
as well as a responsible molecule for apoptosis and oxidative stress (70-72). 
Two NF-kB activation pathways are well investigated. Inhibitor of NF-kB (IkB) 
kinase (IKK)-IkB-p50/pREL-A (p65) is involved in classic NF-kB signal pathway. 
IKK is composed of two catalytic subunits, namely IKKα and IKKβ, and a regulatory 
subunit IKKγ. IKKβ can phosphorylate IkB-α and IkB-β induces its proteasomal 
degradation. NF-kB-inducing kinase (NIK)-IKK-p100/p65-p52/REL-B is the key 
molecular in NF-kB alternative pathway. The alternative pathway contains the 
upstream pertain kinase NIK, which phosphorylates IKK-α homodimers, resulting the 
phosphorylation of p100. P52 is degraded from p100 in proteasome. The degradation 
of IKK releases the NF-kB dimerization and leads to nuclear translocation of NF-kB 
to activate gene transcription (24). 
IkBα proteosomal degradation and NF-kB DNA binding in the human lung has been 
well studied. Smoker with stable COPD has decreased level of IkBα than nonsmokers 
(73). Cigarette smoke induced NF-kB DNA activity in the mice lung in vivo (74). 
NF-kB was mainly activated in bronchial epithelial cells, CD4+ T cells, CD8+ T cells 
and airway macrophages in COPD patients. The activation of NF-kB was not 
observed in neutrophils (27). NF-kB regulates the expression of IL-1 and TNF-α in 
MonoMac6 with stimulation of aqueous cigarette smoke extract (CSE) (28, 75).  
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1.1.5 The role of MMPs in COPD   
 
COPD is defined as airway and systemic inflammation and airway obstruction (4, 5). 
The protease/antiprotease imbalance, apoptosis/proliferation and oxidative stress 
induced cell dysfunction related tissue remodeling are not well understood. Most 
study of tissue remodeling in lung relate to the protease/antiprotease imbalance theory 
(76-78).  
 
 
1.1.5.1 The MMP family 
 
Matrix metalloproteinases (MMPs) are zinc binding enzymes for the degradation of 
extracellular matrix (ECM). They play an important role in various biological process, 
such as angiogenesis, tumor invasion, bone development and wound healing (79-82). 
They are also involved in regulation of inflammation. MMPs comprise at least 24 
proteolytic enzymes in human. According to subsrate the MMPs can be divided into 
collagenases (MMP-1, -8, -13), gelatinases (MMP-2, -9), stromelysins (MMP-3, -10, 
-11), matrilysin (MMP-7), macrophage metalloelastase (MMP-12), membrane-type 
MMPs (MMP-14, -15, -16, -17) and other MMPs (55). The major inhibitors of the 
MMPs are the nonspecific inhibitor α-2 macroglobulin and specific inhibitor, the 
TIMP family proteins (55).  
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Figure.1.3 
 
Figure.1.3. Domain structure of the MMP family.  
The common domain structure of MMPs are the signal peptide (SP), propeptide (Pro), catalytic domain 
(Catalytic), hinge region, and mainly include the hemopexin like C-terminal domain. MMP-7 and -26 
have the minimal domain structure contained only signal peptide, propeptide and catalytic domain. 
MMP-1, -3, -8, -10, -12, -13, -18, -19, -20, -22, -27, ColA and ColB have the basic domain with thiol 
group. MMP-11 and -28 are the furin-activated MMP. MMP-14, -15, -16, -24 are the membrane 
anchored MMP, and contain the transmanbrane domain, cytosolic domain and 
glycosylphosphatidylinositol (GPI) anchor domain. MMP-2 and -9 are the gelatinases. MMP-23 is the 
type II membrane MMP. C5, type-V-collagen-like domain; Col, collagen-like protein; Fn, fibronectin 
repeat; Cs, cytosolic; Cys, cysteine array; Fr, furin-cleavage site; SH, thiol group; Pro, pro-domain: SP, 
signal peptide; Zn, zinc (sourced from Parks WC, et al, 2004) 
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The MMPs contain a common domain structure, the pro-peptide, the catalytic domain, 
and the hemopexin-like domain. The pro-peptide domain is responsible for the 
activation of MMPS, since the remove of pro-peptide induces the activation of 
zymogen. The pro-peptide domain consists of 80 amino acids and with a conserved 
sequence PRCXXPD, which interacts with zinc ion. The catalytic domain contains the 
zinc ion, which bind three conserved histidine residues with conserved sequence 
HEXXHXXGXXH. The catalytic domain links the hemopexin-like domain through 
hinge region. The hinge region is about 75 amino acids. The hemopexin-like 
C-terminal domain is similar as the hemopexin. This domain is responsible for the 
substrate recognition and binding with TIMPs (83). 
 
 
1.1.5.2 The role of MMPs in the degradation of ECM 
 
As described before, MMPs cleavage the connective-tissue elements. The first MMP, 
which was discovered by Gross and Lapiere in 1962 (84), was found as an 
collagenase for neutral pH. The discovery of MMP function is based on identification 
of its physiological substrates (85). All MMPs have been shown to be able to degrade 
various protein components of the ECM (86). MMPs induced ECM degradation has 
been well studied in in vitro systems. The co-incubation of purified MMP and purified 
ECM protein under optimal conditions verified ECM cleavage function of MMPs. 
various studies indicate that some MMPs show effect on ECM proteins. Under 
situations, such as an inflamed tissue or tumor, the MMPs is involved in diverse 
biological process such as angiogenesis, phagocytosis and remodeling. Diverse cells 
produce a spectrum of MMPs, which have different localization and various functions. 
MMP secreted by macrophages would probably function different function than 
which secreted from epithelial cells. The same MMP may have several substrates in 
same tissue. Recent studies support that multiple functions of MMPs are not always 
refers to ECM degradation. The using of MMP inhibitors in clinical trials is a new 
beneficial and prospect MMP function. 
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1.1.5.3 The role of MMPs in inflammation 
 
Inflammation is a complex biological response to harmful stimuli. The inflammatory 
process is a complicated physiological process. Inflammation is initiated mainly from 
leukocyte such as macrophages, dendritic cells, neutrophil and mast cells which 
already exist in tissues. The upregulation of MMPs is observed in many diseases that 
are associated with inflammation (87). A hallmark of the inflammatory process is the 
matrix proteolysis. The function of MMPs as matrix degrading proteinases contributes 
to their function in the inflammation. MMP inhibitors are used as anti-inflammatory 
drugs (88) and have been considered as a mediator to inhibit tissue destruction in 
some inflammatory diseases (89, 90). The exact function of MMPs in inflammatory 
diseases remains poorly understood. But some mouse studies indicate that MMPs, 
such as MMP2 and MMP3, are associated with joint destruction and may provide 
protection (91). MMP-12 is produced mostly by alveolar macrophages, smooth 
muscle cells, and epithelia in response to cigarette smoke. It is a key molecule in the 
recruitment of inflammatory cells. MMPs also contribute to some repair processes and 
leukocyte recruitment, which are central processes to inflammation. 
 
 
1.1.5.4 The MMPs in COPD 
 
Patients with COPD caused by cigarette smoke showed elevated MMP-2, -9, and -12 
in alveolar macrophages (92). MMP-12 is related to acute and chronic pulmonary 
inflammatory diseases such as COPD and other smoking related injury. COPD 
patients have elevated MMP-12 than controls, ant it indicates that MMP-12 may play 
an important role in the pathogenesis of COPD and emphysema (93). MMP-12 
knockout (KO) mice exposed to cigarette smoke showed reduced lung injury. 
MMP-12 KO mice exposed to long-term cigarette smoke showed also macrophage 
recruitment in lungs (94).  
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MMP-12 is one of the most important proteinases which are responsible for airway 
wall destruction. COPD patients produce MMP-12 protein in the sputum, BAL, 
bronchial biopsies (85, 95, 96), and also in lung tissue. MMP12 expression in mRNA 
and protein level was also observed in alveolar macrophage and lung tissue of animal 
COPD model using C57BL/6 mice (97). The expression of TIMP-1 and -2 was not 
observed (98).  
MMP-12 acted in macrophage as TNF- converting enzyme, induced the release of 
active TNF-α from macrophages and initiated a cascade of inflammatory responses. 
TNF-α mostly promotes the recruitment of neutrophils to the lung. These acute 
pulmonary inflammation were independent on NF-kB pathway. Some studies using 
MMP-12-null mice showed same rapid increase of NF-kB DNA binding activity as 
and wild-type mice (99). 
Increasing evidence indicate that MMP-12 not only express in macrophages but also 
in other cells. MMP-12 was also released from dendritic cells, and the dendritic cells 
expressed increasing MMP-12 after stimulation with aqueous CSE (100).  
 
 
1.1.6 Toll-like receptors 
 
In 1985, the toll gene was firstly identified in Drosophila in Germany(101). Toll-like 
receptors (TLRs) belong to the pattern recognition receptor (PRR). To date, 13 
principle members comprising TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, 
TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13 descript (102-105) have been 
reported in human and mouse. The TLR11, TLR12, and TLR13 are not present in 
human (106). TLRs are believed to play an important role in both innate and adaptive 
immunity. The study in Drosophila outlined the role of TLRs in innate immunity, thus 
Drosophila has only innate immunity system. The presence of TLRs in dendric cells 
indicated the link of TLRs in both innate and adaptive immunity (107). Our 
understanding about the function of the TLRs is mostly focus on the recognition of 
the pathogen and the associated molecule of infectious diseases.  
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To date, the ligands of TLRs are well studied. TLR3, TLR7, TLR8 and TLR9 are 
activated by nucleic acid derived from viruses, and induced the release of 
inflammatory cytokines such as type I interferons. TLR3 is activated by 
double-stranded viral RNA (108). TLRs 7 and 8 are activated by single-stranded 
RNAs (109, 110). TLR9 is an important receptor for respiratory disease, thus it 
activated by bacterial DNA known as Cytosine–guanine Pairs DNA (CpG DNA) 
(111)and Herpes viruses (112). 
 
TLR2 and TLR4 are activated by the bacterial membrane components known as 
bacterial peptidoglycans or lipopolysaccharides. TLR4 is also reported to be activated 
by pneumolysin derived from Streptococcus pneumonia (113). TLR2 is activated by 
lipoprotein derived from Gram-positive bacteria and mycobacteria (114, 115), and 
also activated by some lipoproteins from wide range of microorganisms such as 
Borrelia burgdorferi, Treponema pallidum, Aspergillus fumigatus and Mycoplasma 
fermentes. TLR2 and TLR4 are also reported to activated by some host prorein such 
as defensins (116), ROS (117), surfactant protein A (103) and fibrinogen (118).  
 
 
1.1.7 Toll-like receptor signaling 
 
The TLR signaling is well studied in recent papers (119-121). TLRs have a 
leucine-rich repeats in extracellular domain, which thought to be important for the 
ligand recognition. The TLRs have an about 200 amino acids region named TIR 
(Toll/IL-1R) domain, which shares the same sequence as IL-1R, and thought to be 
crucial for the signaling. The point mutation of TIR in C3H/HeJ mouse indicated the 
role in TLR4 signaling 51. The TIR domain serves as a negative regulation of many 
signaling pathway such as MAPKs (mitogen-activated protein kinases), PI3K 
(phosphoinositide 3-kinase) and NF-κB (nuclear factorκB) (120). TLR3 and TLR4 
regulate the release of type 1 IFNs by activation of the IRF3 (IFN regulatory factor 3), 
and induced further IFN-dependent gene expression (122).  
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The adapter protein of the TLRs included the MyD88, Mal (MyD88 
adapter-like)/TIRAP (TIR-domain-containing adapter protein), TRIF/TICAM1 and 
TRAM/TICAM2 were also well studied recently. Normally accepted is the TLR 
signaling can be divided into two different signaling: the MyD88-dependent and 
TRIF-dependent or MyD88-independent pathway (113, 114, 123). 
 
The MyD88-dependent TLR signaling is shared by all TLR but TLR3. The TLR 
ligand binds the TLR, then recruits the MyD88, and induced the accumulation of 
IRAK4, IRAK1 and IRAK2. IRAK kinases phosphorylate the TRAF6. The TRAF6 
then phosphorylates IKK-β, and activates the NF-κB signaling in order to release the 
inflammatory cytokines (120). 
 
TLR3 and TLR4 signaling are the typical TRIF-dependent or MyD88-independent 
pathway. dsRNA and LPS activate the TLR3 and TLR4, induced the recruitment of 
TRIF. TRIF induced the activation of TBK1 and RIPK1, which activated the RIF3, 
and the RIF3 then translocated to nucleus, and induced the activation of TAK1 and the 
transcription of NF-κB, which induced the inflammatory response. Only TLR4 uses 
all four known adaptor proteins (120). 
 
 
1.1.8 The expression of TLRs in lung 
 
The lung is the main place for the innate immunity. In lung, the airway epithelial cells, 
alveolar type II epithelial cells and the immunocells such as macrophage and dendric 
cell express TLRs (124-128). Subcellularly, TLRs are expressed not only on the cell 
surface but also within extracellular organism of cells. The expression of TLR1, TLR2 
and TLR4 are located on the cell surface by positive staining of TLRs with specific 
antibodies. However, TLR3, TLR7, TLR8 and TLR9 shown to be located in 
intracellular compartments such as endosomes (128-131). Macrophages and dendritic  
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cells can engulf the microbial component by phagocytosis in case of infection. TLRs 
involved also in phagocytosis. The target deletion of TLR2/TLR4 or MyD88 induced 
abnormal phagocytosis of bacteria such as Escherichia coli, Salmonella typhimurium 
and Staphylococcus aureus by abnormal phagosome maturation (132). The 
mechanism of TLR9 expression can be hypothesized that in case of phagocytosis of 
microbial organism by macrophage or dendric cells the degradation products such as 
CpGDNA from bacteria released from phagosomes or endosomes and then induced 
the expression or recruitment of TLR9 in phagosomes or endosomes. Of viral 
infection, the virus are degradated in the endosomal compartment results the 
expression of dsRNA and ssRNA, which known as TLR ligands, then induced the 
recruitment of on cell surface expressed TLRs like TLR2 (133).  
 
 
1.1.9 The Toll-like receptor in response of CS 
 
Bacterial components such as lipopeptides of NTHi, LPS of Gram-negative bacteria 
and flagellin of Pseudomonas aeruginosa are able to activate the TLRs of alveolar 
macrophage such as TLR2, TLR4 and TLR5 (114, 134-136). The activation of TLRs 
activates intracellular signaling pathway such as mitogen-activated protein kinases 
(MAPK) and NF-κB. COPD patients in stable state or in acute exacerbation have 
bacterial or viral colonized in airway (137-139). Therefore the activation of TLRs in 
COPD patients in stable or exacerbation state may always exist.  
There are studies demonstrate that the release of proinflammatory cytokines such as 
IL-6 and TNF-α in smoker’s alveolar macrophage after stimulation with LPS were 
significantly decreased compare to controls (140, 141). The reduced inflammatory 
response of smoker’s alveolar macrophage is associated with negative regulation of 
NF-κB and p38 MAPK pathway. This effect was also confirmed in vitro study. CSE 
suppressed the gene expression of proinflammatory cytokines in smoker’s alveolar 
macrophage except IL-8, which known as neutrophil chemoattractant (142-144). 
Furthermore, there are also studies reported that alveolar macrophage from COPD  
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patients has impaired phagocytosis (145, 146). Accumulated studies indicated that 
TLRs and p38 MAPK may play a key role in the innate immunity in COPD. 
 
 
1.2 COPD exacerbation 
 
Acute exacerbations of COPD (AECOPDs) are common in the COPD patient. For 
example, in the United Kingdom, each COPD patient has a frequency of 0.8–2.5 
AECOPD per year (147). Severe AECOPDs particularly require hospitalization. In the 
UK, 34% of COPD patients of emergency hospital admission were readmitted and 14% 
patients were dead within 3 month of discharge (148). Furthermore, AECOPDs, 
resulting a significantly higher health care costs, service and a burden to society (149).  
 
 
1.2.1 Risk factors of COPD Exacerbation 
 
The main risk factors in acute exacerbations of COPD are thought to be respiratory 
infection including viral and bacterial infections, as well as air pollutants. 
 
 
1.2.1.1 Bacterial Infection in COPD exacerbations 
 
Non-typeable Haemophilus influenza (H.i), Moraxella catarrhalis (gram-negative 
bacteria) and Streptococcus pneumoniae (gram-positive bacteria) are the three most 
common isolated bacterial pathogens from respiratory tract infections in COPD 
patients. Some atypical bacteria, especially Chlamydia pneumonia, have also been  
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detected to be able to cause COPD exacerbations (150). 25 to 50% of COPD patients 
are colonized by bacteria in the lower airways, especially Non-typeable Haemophilus 
influenzae, Streptococcus pneumonia, and Moraxella catarrhalis (151). This 
colonization plays an important role in the severity of COPD and cigarette smoking 
(152, 153). The bacterium in the lower airways of stable COPD patients stimulates 
host defense mechanisms that induce increased airway inflammation (154). These 
bacteria are different in stable COPD patients, and the patients with high exacerbation 
frequency of bacterial infection exhibit faster impaired lung function (155). A recent 
study showed that the sputum IL-8 levels and bacterial load are related with FEV1 in 
COPD patients (156). The exacerbation frequency in COPD patients is dominantly 
increased with an increased airway bacterial load (157). Antibiotic therapy is useful 
for the clearance of bacterial load, the clearance of bacteria from the sputum and 
decreased airway inflammation in airway (158). Taken together, the bacterial infection 
in the airway during exacerbations of COPD patients led to increased airway 
inflammation and decreased lung function. 
 
 
1.2.1.2 Viral Infection in COPD exacerbations 
 
COPD patients infected with virulent strains, for example H. influenza, often show 
severe airway inflammation than bacterial infection. It suggested that virulent strains 
may be more dangerous than colonizing strains (150, 159). Almost 50% of COPD 
exacerbations are associated with viral infections, the major viral infection are due to 
rhinovirus (160). Rhinoviruses are the most frequently identified virus during 
exacerbations in COPD patients. Rhinovirus can be recovered from sputum more 
frequently than from nasal aspirates at exacerbations. This study suggested that 
wild-type rhinovirus is able to infect lower airways and contribute to inflammatory 
changes at exacerbation. COPD exacerbations associated with the presence of 
rhinovirus induced higher airway IL-6 levels. It indicated that viruses induced more  
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severe airway inflammation during COPD exacerbation (63). Respiratory viruses 
result normally longer and severer air way inflammation than bacteria and have a 
major impact on health care burden (42, 160). The systemic inflammatory markers  
 
were also increased in serum from viral infected COPD patients (63). The major 
receptor of rhinoviruses is intercellular adhesion molecule (ICAM)-1. Increased 
epithelial expression of ICAM-1 indicates the infection of rhinovirus. Some studies 
indicated the increased ICAM-1 in COPD exacerbation patients (161). Additionally, 
rhinovirus stimulate mucus secretion from airway epithelium (162). 
 
 
1.2.1.3 Air Pollution in COPD exacerbations 
 
Epidemiologic studies indicate that air pollution can induce COPD exacerbations 
(163). Outdoor and indoor air pollution was mostly produced by biomass fuel and 
volcanic eruption (164). The outdoor pollution has been reported to affect the lung 
development in teenage of 10-18 years (165). The epidemiologic studies in the US  
and Europa significantly support the correlation between outdoor pollution and 
hospital admission of COPD patients (166). The increased level of sulfur dioxide 
(SO2), nitrogen dioxide (NO2) and O3 is strong related to increased mortality of 
COPD patients (167-169). Some clinical studies indicated that air pollution may 
account for 6 to 9% of hospitalization in COPD patients (168). In total, air pollution 
may lead to exacerbations of COPD. 
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1.2.2 The airway inflammation during COPD exacerbation 
 
Exacerbations are highly related with airway inflammation. An increased airway 
inflammation is strong associated with the pathogenesis of exacerbations. Airway 
inflammation could result in airway wall edema and increased mucus secretion. 
Increased mucus secretion thought to be an important phenotype of acute episodes of 
COPD. The increased sputum secretion in the airways would reduce the airway 
diameter and this effect would be enhanced with increased viscosity of the sputum. 
On the cellular level, the inflammatory phenotype of the airways is characterized by 
increasing infiltration of macrophages, neutrophils and CD8+ T lymphocytes in the 
airway wall and in air space (170). At exacerbations the cellular pattern will be 
changed. Eosinophils and neutrophils change to be the major component of the 
inflammatory response (170, 171). Recently, T cell-mediated immunity has been 
detected in sputum samples at exacerbations. CD4:CD8 ratio is decreased and 
observed during severe episodes of hospitalization (172). These results indicate that T 
lymphocyte subpopulations may be correlated with the development of COPD 
exacerbations. 
 
Currently, soluble mediators are used as indirect markers of airway inflammation. 
Endothelin-1 is one of the marker of airway inflammation, which is expressed from 
the bronchial and pulmonary epithelium and alveolar macrophage, may result mucus 
secretion (173). 
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1.3 Aim of this work 
 
The aim of this work is to establish a new mouse model for COPD development, in 
order to investigate the interaction of CS and H.i and to preliminary study the cellular 
and molecular mechanisms of the pathogenesis of COPD exacerbation, and provide 
the new approach to the treatment of COPD exacerbation.  
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Laboratory apparatus 
 
Autoclave              Holzner Medizintechnik GmbH, Nußloch 
                      Systec GmbH Labor Systemtechnik, Wettenberg 
 
Analytical balance       Kern & Sohn GmbH, Balingen 
 
Agarose gel-apparatus     FB-SB-1316 Electrophoresis Systems  
                       FisherBiotech, Wembley, Australien 
 
BD FACSCanto™ II    BD, Heidelberg, Germany 
 
Centrifuges             Centrifuge 5415R, Eppendorf AG (Hamburg) 
                       neoLab-mini-centrifuge, neoLab GmbH,  
Heidelberg 
                       Rotanta/TR, Hettich GmbH & Co.KG, Tuttlingen 
                       Beckman Coulter GmbH, Krefeld 
 
Fluorescence plate reader   Tecan Ultra384  
                       Tecan Austria GmbH 
 
Ice machine              Scotsman Frimont AF20,  
                       HIBU Eismaschinen GmbH & Co. KG,  
Sprockhövel 
 
Incubators               Nu-5100, Integra Biosciences GmbH, Fernwald 
                       Heraeus* Function Line Microbiological  
Incubators, Heraeus Holding GmbH, Hanau 
 
Microscope              BX51 Olympus, Olympus GmbH, Hamburg 
 
Microwave              Sharp Electronics GmbH, Hamburg 
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NanoDrop             Thermo Fisher Scientific GmbH, Schwerte 
 
 
pH-meter            20-SevenEasyTMpH, Mettler-Toledo GmbH, Giessen 
 
 
Photometer UItrospec 2100 pro, Amersham Pharmacia, 
Uppsala, Sweden 
 
Power-Supply          Consort EV231, Consort, Turnhout, Belgien 
                     Thermo Electron Corporation, Waltham, USA 
 
Real Time PCR Machine   MyCycler, BioRad 
 
SDS PAGE apparatus   Mini PROTEAN 3 Cell,  
        Bio-Rad Laboratories GmbH, München 
 
Speed vac      Eppendorf concentrator 5301  
 
Water bath      W19, Haake 
 
Western Blot apparatus   Biorad 
 
 
 
2.1.2 Chemicals and reagents 
 
β-Mercaptoethanol    Roth, Karlsruhe, Germany 
 
Polyacrylamide (37.5:1)       Roth, Karlsruhe, Germany 
 
APS                 Sigma, Steinheim, Germany 
 
BSA                 Calbiochem, Darmstadt, Germany 
 
Citric acid monohydrate         Roth, Karlsruhe, Germany 
 
Ethanol               Roth, Karlsruhe, Germany 
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Glycerin                Roth, Karlsruhe, Germany 
 
Glycine                 Roth, Karlsruhe, Germany 
 
H2SO4                Roth, Karlsruhe, Germany 
 
HCl                  Roth, Karlsruhe, Germany 
 
Methanol                Center of chemical storage, 
         University of Saarland 
 
NaCl                  Roth, Karlsruhe, Germany 
 
NaH2PO4. H2O             Merck, Darmstadt, Germany 
 
Na2HPO4       Fluka, Buchs (CH), Germany 
 
NaOH                 AppliChem, Darmstadt, Germany 
 
Paraformaldehyde            Roth, Karlsruhe, Germany 
 
Protein Standard (SeeBlue® Plus2)   Invitrogen, Carlsbad, CA, USA 
       
Skim milk                Roth, Karlsruhe, Germany 
 
SDS                  Roth, Karlsruhe, Germany 
 
TEMED                Sigma, Steinheim, Germany 
 
Tris base                Sigma, St. Louis, MO, USA 
 
Tween® 20               AppliChem, Darmstadt, Germany 
 
TRIzol® Reagent     Invitrogen, Carlsbad, CA, USA 
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2.1.3 Consumable laboratory supplies 
 
All cell culture     Greiner bio-one (Frickenhausen)  
Materials    
 
Cannula 23/25G     Microlance 3 Needles, Becton Dickinson GmbH,  
        Heidelberg 
 
Cuvette       10x4x45 mm, Sarstedt AG & Co.KG, Nümbrecht 
 
Membrane (Western Blot)  Immobilon-p Transfer Membrane PVDF Pore 
        Size 0,45μl, Millipore 
 
PCR-reaction tubes    Biozym Scientific GmbH, Hess. Oldendorf 
 
1.5 ml and 2.0 ml    SafeSeal Reagiergefäße, Sarstedt AG & Co.,  
reaction tubes      Nümbrecht  
 
15 ml and 50 ml     Greiner Bio-One, Frickenhausen  
sterile tubes  
 
 
2.1.4 Antibodies 
 
anti p65 (C20) Rabbit, polyclonal, IgG, Santa Cruz Biotechnology, 
Heidelberg 
 
anti actin (H-196) Rabbit, polyclonal, IgG, Santa Cruz Biotechnology, 
Heidelberg 
 
anti MMP12(EP1261Y)  Rabbit, monoclonal, IgG, Abcam plc, Cambridge 
 
anti CD3     Rabbit, polyclonal, IgG, Abcam plc, Cambridge  
 
anti CD22     Rabbit, polyclonal, IgG, Abcam plc, Cambridge 
 
anti CD68     Rabbit, polyclonal, IgG, Abcam plc, Cambridge 
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2.1.5 Bacteria 
 
non-typeable Haemophilus influenza  kindly obtained from clinical microbiology of 
University of Saarland 
 
 
 
 
2.1.6 Primers 
 
The following PCR primers (Metabion, Martinsried, Germany) were used in this work 
 
Name Sense primer Antisense primer Tm 
mouse MMP2 5’-TCTTCTTCAAGGACCGGTTTATTTGG-3’ 5’-TGAAGAAGTAGCTATGACCACCACCCT-3’ 60°C 
mouse MMP9 5’-CTTCTGCCCTACCCGAGTGGAC-3’ 5’-AGGCTTAGAGCCACGACCATACAGA-3’ 60°C 
mouse MMP12 5’-TGCATTTGGAGCTCACGGAGACTT-3’ 5’-GAAGCTTCCACCAGAAGAACCAGTCTT-3’ 60°C 
mouse TIMP1 5’-TCCCCAGAAATCAACGAGAC-3’ 5’-CACAGACTTCAGCGAATGGA-3’ 60°C 
mouse TIMP2 5’-CACAGACTTCAGCGAATG-3’ 5’-CTTGGGAAGCTTGAGAGTGG-3’ 60°C 
mouse 
Neutrophil 
elastase 5’-GGCTTTGACCCATCACAACT-3’ 5’-CGGCACATGTTAGTCACCAC-3’ 60°C 
mouse β-actin 5’-AGCCTCGCCTTTGCCGA-3’ 5’-CTGGTGCCTGGGGCG-3’ 60°C 
human GAPDH 5’-AGGTCGGAGTCAACGGATTTGGT-3’ 5’-GTGCAGGAGGCATTGCTGATGAT-3’ 60°C 
human MMP12 5’-ACACATTTCGCCTCTCTGCT-3’ 5’-AAGCAGCTTCAATGCCAGAT-3’ 60°C 
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2.2 Methods 
 
2.2.1 Animal Studies 
 
All animal experiments in this study were performed in accordance with and approved 
by the “Landesamt für Soziales, Gesundheit und Verbraucherschutz” of the State of 
Saarland following the national guidelines for animal treatment. The animals were 
housed under pathogen free conditions in the animal facility of the institute for 
experimental surgery at the Saarland University Hospital, Homburg. The 8 to 10 week 
old female wild type C57BL/6N mice used for this study were purchased from 
Charles River (Sulzbach, Germany). 
 
 
2.2.2 Cigarette smoke extract (CSE) preparation 
 
84mm filtered research cigarettes grade 3R4F (36.8 mg tar and 2.45 mg nicotine) 
were bought from university of Kentucky in United States. Cigarette was burned with 
peristaltic pump into 10 ml DMEM medium in 2 min. The CSE extract was sterilizly 
filtered with a 0.2µm pore acrodisc® syringe filter (Pall Corporation, Ann Arbor, MI) 
for removing bacteria and other large particles in medium. This CSE extract was 
considered as 100% concentration. This CSE extract was aliquoted in 500µl stock and 
frozen immediately in -80°C. 
 
2.2.3 H.i-lysate preparation 
 
Clinical isolated H.i strain was kindly received from the Institute of Pathology of the 
University hospital of the Saarland, Homburg and was stored as frozen stock (1x107  
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colony-forming units/ml). H.i in stock was confirmed by 16S rDNA PCR analysis. H.i 
was grown on chocolate agar with IsoVitaleX at 300µl per 10-cm plate (BD, Heidelberg, 
Germany) for 24 hours at 37°C, 5% CO2. After this, the H.i is harvest and incubated for 
24 hours in 700mL brain-heart infusion broth (BD, Heidelberg, Germany) containing 3.5 
mg/ml NAD (Sigma-Aldrich, St. Louis, MO) and 5% Fildes enrichment (BD, 
Heidelberg, Germany). The culture was centrifuged at 2,500g for 15 minutes at 4°C, 
washed with ice cool PBS for 1 time then resuspended in 20 ml PBS, and heat 
inactivated at 70°c with shaker for 45min, then sonicated for 3 times of 30 seconds in 
a 50ml plastic tube. Protein concentration was adjusted to 2.5 mg/ml in PBS with 
bicinchoninic assay (Pierce, Rockford, IL), and the H.i lysate was frozen in 7 ml 
aliquots at -80°C. The inactivation of H.i was also confirmed by grown the H.i lysate 
on chocolate agar with IsoVitaleX for 24h at 37°C in 5% CO2. 
 
 
2.2.4 Cigarette smoke exposure 
 
Male C57/BL6N mice were exposed to smoke with 3R4F reference cigarettes 
(College of Agriculture, Reference Cigarette Program, University of Kentucky, 
Lexington, USA) in a TE-10 smoking machine (Teague Enterprises, Woodland, 
California, USA) for 3 hours and 5 days per week. The total suspended particles (TSP) 
concentration was 120 mg/m3. The TSP was measured by gravimetric methods as 
advised by the manufacturer and controlled in regular intervals. The total duration of 
the smoke exposure was from 2 weeks up to 6 months. 
 
 
2.2.5 H.i-lysate challenge 
 
The mice were placed in a plexi glass box connected to a Pari MASTER® nebulizer  
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(Pari GmbH, Starnberg, Germany) and exposed to the inactivated bacterial lysate for 
40 minutes either daily (high dose H.i., hd-H.i.) or once per week (low dose H.i., 
ld-H.i.) at a concentration of 2,5 mg of total bacterial protein. The protein 
concentration was measured by the Pierce BCA-protein assay (Thermo Fisher 
Scientific Inc., Rockford, IL, USA). 
 
 
2.2.6 Animal preparation 
 
At the endpoints of the experiments the mice were anesthetized by an i.p. injection of 
a ketamine and xylazin mixture. The chest was opened and blood was drawn from the 
heart for the preparation of serum and the analysis of inflammatory cytokines. The 
trachea was exposed and cannulated with an 18G cannula. Bronchoalveolar lavage 
(BAL) was performed by 3 times instillation of 1 ml sterile filtered phosphate 
buffered saline (PBS) including protease inhibitors (Complete protease inhibitor 
cocktail, Roche Applied Science, Mannheim, Germany). The lung was removed and 
the right lobes were homogenized in protein extraction buffer (PBS with protease 
inhibitor cocktail) and immediately frozen in liquid nitrogen. The left lobe was used 
for RNA extraction by Trizol. 
 
 
2.2.7 Lung function 
 
Lung function was performed with a FlexiVent system (EMKA Technologies, Paris, 
France). The mice were anesthetized by a mixture of ketamine and xylazine. The 
trachea was exposed and cannulated using the cannula included with the FlexiVent 
system. Mice were placed on a plastic plate as described previously (174-176), and 
stabilized in the cages for 5 minutes. In the single compartment model the lung is  
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recognized as on compartment and Respiratory system resistance (Rrs), Respiratory 
system elastance (Ers), and Respiratory system compliance (Crs) are calculated based 
upon SnapShot-150. The maneuver PVs-P calculates Vital capacity (A), Quasi-static 
compliance (Cst), and Quasi-static elastance (Est) based on the Salazar Knowles 
equations. In the constant phase model the parameters Central airway resistance (Rn), 
Tissue damping (G), Tissue Elastance (H), and Inertance (I) are calculated based upon 
the QuickPrim3 maneuver. All maneuvers are repeated at least in triplicate. 
 
 
2.2.8 Stereological quantification of emphysema 
 
After lung function measurements the lung was removed completely and fixed with 
fresh 4% formalin in PBS-buffer of constant hydrostatic pressure of 20 cm H2O for 20 
minutes. Then the trachea was ligated in order to contain constant intrapulmonary 
pressure for the embedding of lung tissue. The whole lung was through in to 25 ml 
plastic tube with same formalin-PBS solution for 72 h. The lung volume was 
determined by fluid displacement. Then the fixed lung was embedded in paraffin and 
cut to slides of 1µm thickness for stereological and immunohistochemistry analysis. 
The mean chord length (mean linear intercept, Lm) was measured by random sampling 
using the Visiopharm Integrator System (Visiopharm, Hoersholm, Denmark) on an 
Olympus BX51 microscope (177). 
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2.2.9 Real-time PCR 
 
The mRNA expression was measured using quantitative real-time PCR. We isolated 
the total DNA using 3 ml TRIzol reagent (Invitrogen, Carlsbad, CA, USA) for the 
homogenization of 1/4 lung-tissue. We used 1.5 µg RNA for the reverse transcription 
with First Strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany). Total 
25-µL SYBR-Green-PCR mixed with 1:9 diluted cDNA as template. The SensiMix 
SYBR & Fluorescein Kit (Bioline, Luckenwalde, Germany) was used for the RT-PCR. 
iCycler machine was bought from Bio-Rad in Munich, Germany. The program of 
RT-PCR is listed below. 
 
Step Cycle Temperature Time 
polymerase activation 1 95°C 15 min 
denaturation 
anneal 
extension 
45 95°C 
Tm 
72°C 
30 sec 
30 sec 
45 sec 
final extension 1 72°C 3 min 
denaturation 1 95°C 1 min 
start-temperature 1 55°C 1 min 
melt temperature 80 
55°C (+0.5°C 
/cycle) 
10 sec 
 
We analyzed the results using ΔΔCT (cycle threshold) method. GAPDH levels was 
used for the normalization of each sample.  
 
 
2.2.10 Immunohistochemical analyses 
 
The lungs were prepared as described before and incubated at 60°C overnight. After  
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deparaffinization sections were heated at 100°C for 20 min in 0.01 M citrate buffer 
(pH 6.0) for antigen retrieval. 3% (v/v) H2O2 was used for blocking of the unspecific 
tissue peroxidases and followed by incubation in blocking solution (2% BSA in 
TBS-T) for 60 min to prevent nonspecific binding. Slides were incubated with 
primary antibodies at 4°C overnight. Secondary antibody incubation and staining 
were performed using the EnVision®+ System–HRP (AEC) kit (Dako, Carpinteria, 
CA, USA) according to manufacturer’s recommendations. The sections were 
counterstained with hematoxylin. Rabbit anti-MMP12 (1:1000) (for mouse, 1:1000, 
ABCAM, Cambridge, UK) antibody was used in this work: rabbit anti-MMP12 (for 
mouse, 1:1000, Abcam, Cambridge, UK), mouse anti-MMP12 (1:1000) (for mouse, 
1:1000, ABCAM, Cambridge, UK).  
 
2.2.11 Heidenhain s´ Azan stain 
 
Samples were prepared as described before and incubated at 60°C overnight. After 
deparaffinization sections were rinsed in distilled water for 5 min, and then Incubated 
in warm azocarmine solution for 30 min at 57°C. After rinsing for 5 min in distilled 
water the slides were incubated in 0.1 % alcoholic aniline solution for 3 min, 1% 
acetic acid alcohol for 1 min and 5% phosphotungstic acid solution for 20 min under 
visual inspection. After rinsing briefly in distilled water the slides were incubated in 
aniline blue-Orange-G acetic acid solution for 20 min. Then the slides were rinsed 
briefly in distilled water. Slides were differentiated by a few short immersions in 96% 
ethanol. Then the slides were dehydrated twice in 96% ethanol, cleared in acetic 
acid-n-butylester EBE® (Roth, Karlsruhe, Germany), and finally mounted using 
Promountes® RCM2000 (Medite, Burgdorf, Germany). 
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2.2.12 SDS-PAGE and Western blot 
 
2.2.12.1 SDS-PAGE  
 
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE) is a 
useful method for the separation of different protein according to molecular size. 
Running conditions: 10 min 100 V const. and then about 1h 30 min, 150 V const. The 
glass plates were washed with water and then dried with Kleenex. It was assembled in 
the apparatus. The buffers and reagents for separating gel (12%), except APS and 
TEMED were pipetted together. APS and TEMED were added into the solution and it 
was mixed well by swirling gently. This solution was directly pipetted into space 
between glass plates. Immediately it was overlaid with isopropanol and polymerised 
more than half hour at RT. Then the overlay was pour away, the separating gel was 
washed with water shortly. The prepared stacking gel was pipetted on the separating 
gel until the space was filled completely. A comb was placed in the stacking gel. After 
about 10 min polymerisation the comb was taken away. The gel was assembled in the 
gel apparatus and was immersed in the 1x running buffer. 
 
 
2.2.12.2 Western Blot analysis 
 
The electro blotting (150 mA overnight or 300 mA for 4 h at 4°C) was performed in 
order to blot the protein to nitrocellulose membranes. After blotting the nitrocellulose 
membrane was blocked with with 5% milk in TBST for 30 min. After this, the 
membrane was incubated with diluted primary antibody at 4°C over night. After the 
primary antibody incubation the membrane was wasched 3 time 15 min. The detection 
using Kodak scientific imaging films (Eastman Kodak, Rochester, N.Y., USA) was 
performed by enhanced chemiluminescence kit (Cell Signaling Technology, Danvers,  
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MA, USA). 
 
 
2.2.13 Enzyme-linked immunoabsorbent assay  
 
To determine the concentration of cytokines in Lavage and Lung-homogenate the 
Enzyme-linked immunoabsorbent assay was performed in this work.  
The 96-well PVC micro titer plate was coated with the capture antibody at a 
concentration of 1-10 μg/ml in carbonate/bicarbonate buffer (pH9.6) over night at 4°C. 
After removing the coating solution the plates were washed 3 times by filling the 
wells with 200 μl PBS. And then the plates were blocked with 300µl / well blocking 
reagent for 2-3h at 37°C. The blocking reagent was removed by washing 3 times with 
PBS-T. The samples were normalized to same protein concentration by BCA-Assay 
and were added and incubated over night at 4°C. After washing for 3 times with 
PBS-T the detection antibody at a concentration of 1-10 μg/ml were added and 
incubated for 2h at room temperature. After washing for 3 times 200µl/well of 
Streptavidin-POD conjugate solution were added and incubated at RT for 5-30 min. 
100µl 3N H2SO4 was added to each well and incubated for 1 min on the shaker. The 
absorbance was measured using ELISA reader at 450nm. 
 
 
2.2.14 Cytometric bead assay (CBA)  
 
Cytometric bead assay (CBA) was performed as descript from BD science for 
detecting the concentration of cytokines of bronchial alveolar lavage fluid (BALF) 
and Lung-homogenate. We added respectively 50 μl beads, 50 μl mouse Th1/Th2 
cytokine standard and 50 μl sample into the assay tubes. The mixture was incubated at 
room temperature for 2 h in a dark room. After this, we added 1 ml wash buffer into  
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the tubes. After centrifugation at 200g for 5 min, we removed the supernatant and 
resuspended the pellet with 300 µl wash buffer. All samples were measured on flow 
cytometer. Results were calculated with FCAP Array software. 
 
 
2.2.15 Statistical analysis 
 
We analyzed the data using GraphPrims 5 (GraphPad Software Inc., La Jolla, CA, 
USA) software. The two group was comprised using two side t test. P values less than 
0.05 was considered as significance.  
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3. Results 
It is the goal of this work is to characterize and develop the COPD and AECOPD 
mouse model in response of CS and H.i, additional the pathological mechanisms of 
COPD and AECOPD will be investigated. As previously described H.i colonized the 
lower airways of patients with chronic obstructive pulmonary disease. The 
contribution of H.i in CS induced COPD progression is largely unknown. The basic 
findings of this work in mice provide a new aspect of role of H.i in progression of 
COPD and AECOPD in human.  
In order to determine the role of H.i in CS induced inflammation wild type C57/BL6 
mice were exposed to CS for different time points from 2 weeks up to 6 months and 
additionally were challenged with heat inactivated H.i lysate with different doses at a 
concentration of 2.5 mg/ml of total protein for 40 minus per day and from 1 time per 
week to 5 times per week. An increased inflammation, significant changes in lung 
function and pulmonary remodeling were confirmed in this study. 
 
 
3.1 CS and H.i stimulation did not induce significant loss of 
bodyweight after 6 month. 
 
The wild type C57/BL6 mice were exposed to CS and H.i stimulation from 2 weeks 
up to 6 months. The body weight of the mice was recorded on every Wednesday 
before stimulation with CS and H.i. There was no loss of body weights observed in all 
6 groups at the end of experiment. The health status of mice was also recorded during 
the experiment. Hair loss and shortness of breath was observed in group hd-H.i and 
CS+hd-H.i. The shortness of breath of mice in group CS+hd-H.i occurred more 
frequently than in group hd-H.i, whereas no significant difference of the hair loss of 
mice observed between two groups. 
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Figure.3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.3.1. Effect of cigarette smoke and Haemophilus influenzae exposure on body weight in 
mice. The body weight of every mouse was recorded at every Wednesday before the stimulation with 
CS and H.i. The time point of every Wednesday was considered to be the most suitable for the record 
of body weight, and it thought to be avoided for the influence of the simulation with CS and H.i. A. CS 
group compared with air controlled group. B. ld-H.i compared with air controlled group. C. hd-H.i 
compared with air controlled group. D. CS+ ld-H.i compared with air controlled group. E. CS+ hd-H.i 
compared with air controlled group.  
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3.2 CS and H.i induced influx of leukocytes in lung. 
 
We analyzed the influx and composition of leukocytes into the lung. Neutrophils and 
macrophages are an important source of tissue remodeling enzymes and cytokines that 
in turn are responsible for the regulation of inflammation. The absolute number and 
differential composition of leukocytes in the BALF was analyzed after 2 weeks, 3 
month and 6 month. 
CS stimulation at an average concentration of 120 ± 5 mg/m3 of total suspended 
particles (TSP) for 3 hours per day did not induce a marked cellular influx into 
pulmonary airspaces compared with air controlled mice in 2 weeks, 3 month and 6 
month.  
At 2 weeks, the stimulation with ld-H.i. significantly up regulated the number of total 
cells in the BALF and induced a macrophage dominant inflammation in the lung. The 
total cells in BALF increased to 41 ± 2.3 x 104 cells/ml in BALF, and the percentage 
of neutrophils increased from 0.33% at baseline to 24.56% after ld-H.i exposure in 2 
weeks (Fig. 3.1A).. The H.i stimulation in CS exposed mice changed the phenotype of 
pulmonary inflammation from a macrophage based inflammation to a neutrophilic 
inflammation. The BALF neutrophil percentage of ld-H.i in CS exposed mice was 
significantly higher and changed from 24.56% of only H.i exposed mice to 53.78% 
(Fig. 3.2B) and the relative number of macrophages was significantly lower. hd-H.i 
induced a neutrophil dominant inflammation in BALF compared to ld-H.i stimulation. 
hd-H.i in CS-exposed mice showed also lesser acute increases of neutrophil 
percentage than only hd-H.i (Fig. 3.2B). H&E staining confirmed the influx of 
immunocells in the pulmonary airspace (Fig. 3.2C). CS stimulation did not induce an 
influx of leukocytes in the lung in this model. ld-H.i stimulation caused a marked 
influx of cells the in airspace and around small airways. hd-H.i stimulation in 
CS-exposed mice showed more immunocells influx around airways, blood vessels, in 
alveoli and lymph-follicle like immunocells deposition around small airway compared 
to only hd-H.i stimulated mice.  
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CS exposure for 3 months did not induce a marked influx of leukocytes into BALF 
and pulmonary airspaces. The stimulation with ld-H.i lysate significantly increased 
the number of total cells in the BALF and induced a macrophage dominant 
inflammation in pulmonary airspace. ld-H.i significantly increased lymphocytes 
influx in BALF up to 24.59% of total cells compared 2 weeks ld-H.i. exposed mice. 
An increase of neutrophil percentage in BALF of ld-H.i in CS exposed mice was not 
observed. However the numbers and percentage of lymphocytes was significantly 
decreased in this group (Fig. 3.3B). hd-H.i significantly increased total cells in BALF 
compared ld-H.i, and induced neutrophilia in BALF. hd-H.i in CS exposed mice 
induced a significant increase of total cells compared to only hd-H.i exposed mice. 
The percentage of neutrophils was also significantly increased. 
CS exposure for 6 months induced a slight influx of macrophages into the BALF and 
pulmonary airspaces. The exposure with ld-H.i significantly increased the number of 
immunocells in the BALF and induced a macrophage dominant inflammation in the 
lung such as already observed after 3 months exposure. The percentage of neutrophils 
in BALF of group ld-H.i in CS exposed mice was not increased. The numbers and 
percentage of lymphocytes compared to other 3 H.i exposed groups was significantly 
decreased in this group such as the data at 3 month (Fig. 3.4B). hd-H.i exposure 
significantly increased total cells in BALF compared to ld-H.i, and induced 
neutrophilia in BALF. hd-H.i in CS exposed mice significantly increased total cells 
compared only hd-H.i exposed mice. The percentage of neutrophils was also 
significantly increased. 
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Figure.3.2. CS and H.i stimulation increased the total cell number and altered inflammatory 
phenotype in lung.   
A. total cell count and differential cell count in BALF for 2 weeks stimulation. B. The percentage of 
different cells in BALF for 2 weeks stimulation. C. total cell count and differential cell count in BALF 
for 3 month stimulation. D. The percentage of different cells in BALF for 3 month stimulation. E. total 
cell count and differential cell count in BALF for 6 month stimulation. F. The percentage of different 
cells in BALF for 6 month stimulation. G. H&E staining of lung tissue for 2 weeks stimulation. Results 
are means ± SEM, n=5, ** p<0.01; ***p<0.001.   
 
 
3.3  CS and H.i stimulation significantly increased parenchymal 
remodeling in lung from 3 month. 
 
To confirm the emphysema-like changes in mouse lung following CS and H.i 
stimulation the lung volume and the mean chord length (Lm) were determined. The 
mean chord length (Lm) is a parameter which describes free distance of air spaces. 
 
3.3.1 CS plus hd-H.i stimulation enhanced the parenchymal 
remodeling after 3 month. 
 
CS or H.i stimulation did not significantly enlarge the lung volume at 3 month 
compared the air exposed control mice. But all groups with H.i or CS stimulation 
showed the trend of enlargement of lung volume. hd-H.i and the combination of CS 
and hd-H.i were significantly increased the mean linear intercept. It indicated the 
emphysema-like changes were induced in these two groups.  
The HE staining of paraffin-embedded lung tissue confirmed the destruction of alveoli 
walls and infiltration of immunocells in hd-H.i and CS exposed mice. CS or ld-H.i 
stimulation for 3 month was not induced significant structural changes in lung. hd-H.i 
exposure and combined with CS for 3 month induced significant structural changes in 
lung parenchyma. 
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The lung function inclusive vital capacity, tissue elastance and Quasi-static 
compliance were measured in mice after 3 month. CS and H.i stimulation changed the 
lung functions from 3 month. 
Lung function in 3 month stimulation showed significant decrease in vital capacity of 
ld-H.i, ld-H.i and hd-H.i in CS exposed mice, a significant increase in elastance of 
hd-H.i and a significant decrease in compliance of hd-H.i and hd-H.i in CS exposed 
mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
- 51 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 3.3.1 CS and H.i induced emphysema-like changes in mouse lung after 3 month. 
Mice were treated as described before for 3 months. Lung tissues were fixed and stained with HE, a 
quantitative stereological analysis was undertaken, and then the stereological tests were performed.  A 
Lm was analyzed using uniformly random samples. Results are means ± SEM, n=5, *p<0.05; ** p<0.01; 
***p<0.001. B. C. D. Mice were treated as described before for 3 and 6 month. Lung function was 
performed using a FlexiVent system. The measurement of vital capacity, tissue elastance and 
Quasi-static compliance of CS and H.i exposed mice for 3 month. Results are means ± SEM, n=5, 
*p<0.05; ** p<0.01; ***p<0.001. 
 
  
Figure.3.3.1 
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3.3.2  CS plus hd-H.i stimulation enhanced the parenchyma 
remodeling after 6 month. 
 
hd-H.i and the combination of CS and hd-H.i for 6 months significantly enlarged lung 
volume compared to air controlled mice. CS alone or ld-H.i did not induce significant 
changes in lung volume, but it showed the trend of enlargement of lung volume in this 
3 groups.    
ld-H.i. and hd-H.i induced also significant changes in peripheral alveolar size 
quantified by Lm measurement (Fig. 3.3.2.B). CS alone did not induce significant 
changes in peripheral alveolar size compared to air controlled mice and ld-H.i 
exposed mice. But hd-H.i in CS exposed mice induced significant changes of Lm 
compared to hd-H.i alone. The effect of enlargement of lung volume was also 
confirmed by Lm measurement in Fig.3.3.2.A. 
The peripheral alveolar size quantified by Lm measurement of 3 time points from 2 
week up to 6 months was also figured out in Fig.3.3.2.C. The curve of group CS+ H.i 
hd-H.i. was always above all other groups included group of hd-H.i from 3 months up 
to 6 months. It clearly confirmed that hd-H.i played an important role in the 
destruction of lung tissue in CS exposed mice.  
The HE staining of lung tissue at different time points also confirmed the structural 
changes in CS and H.i exposed mice lung. The lung of every mice in different group 
(n=5) were fixed and stained with hematoxylin and eosin. 2 random selected slices of 
every lung were microscoped. It showed the peripheral alveolar size of ld-H.i, 
CS+ld-H.i, hd-H.i and CS+hd-H.i were marked enlarged after 3 months and the effect 
of destruction of alveolar were enhanced in 6 months. 
The lung function inclusive vital capacity, tissue elastance and Quasi-static 
compliance were measured in mice after 6 month. It showed an increase in vital 
capacity of about 20 %, which correlated with lung volume, a decrease in tissue 
elastance and an increase in compliance in CS treated mice after 6 months. The 
different doses of H.i. caused a decrease in vital capacity, an increase in elastance and 
a decrease in compliance.  While the combination of ld-H.i. and CS showed similar  
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effect like CS alone, the combination of hd-H.i. and CS showed a similar phenotype 
like hd-H.i. alone.  
Lung function of 6 month stimulation compared with 3 month stimulation showed 
enhanced changes in all 3 parameters. The 3 month CS exposure did not significantly 
increase vital capacity, compliance and decreased elastance but in 6 month have 
significantly increased vital capacity, compliance and decreased elastance. The 
combination of hd-H.i. and CS in elastance showed no significant changes in 
elastance in 3 month but significantly increased elastance in 6 month. 
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Figure.3.3.2 
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Figure. 3.3.2 The analysis of Lm from 2 weeks up to 6 month. 
A. The lung volume of 6 months treated mice was measured by fluid displacement. B. The analysis of 
Lm of 6 months treated mice. Results are means ± SEM, n=5, *p<0.05;  ** p<0.01; ***p<0.001. C. HE 
staining of lung tissue. C. The time curve of Lm from 2 weeks up to 6 months. HE staining of mice lung. 
Bar = 50 μm. D. The measurement of vital capacity, tissue elastance and Quasi-static compliance of CS 
and H.i exposed mice for 6 month. Results are means ± SEM, n=5, *p<0.05;  ** p<0.01; ***p<0.001 
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3.4 CS and H.i stimulation induced the expression of 
proinflammatory cytokines in BALF and lung-homogenate 
 
To determine the inflammatory response of H.i in CS exposed mice the Th1, Th2 and 
Th17 cytokines and chemokins such as TNFα, KC, IL-1, MIP1γ, IFNγ, IL-2, IL-17, 
IL-10, and IL-17A were analyzed using CBA or ELISA in BALF and 
lung-homogenate.  
 
3.4.1 CS and H.i stimulation significantly increased proinflammtory 
cytokines in BALF and lung-homogenate at 2 weeks. 
The stimulation with ld- and hd-H.i increased the release of proinflammatory 
mediators such as TNFα and KC in BALF and lung-homogenate. The combination of 
CS and hd-H.i significantly increased the release of TNFα and KC in BALF but not in 
lung-homogenate. CS stimulation caused a significant decrease of IL-1β and MIP1γ 
concentrations in lung homogenate of the hd-H.i treated groups. 
Th2 cytokines include IL-2 and IL-4 play a critical role in skewing inflammation in 
asthma and also prominent in the inflammation observed in COPD patients. In this 
study the release of IL-2 was significantly increased in ld-H.i, hd-H.i and CS 
stimulated mice, whereas TNFα and KC in BALF of CS exposed mice was not 
synergistically increased by H.i stimulation. In addition, hd-H.i significantly 
decreased the release of IL-4 in lung homogenate of CS exposed mice.  
IFNγ is a cytokine which produced from Th1 and Tc1 cells. It usually be found at 
decreased levels in asthmatic patients. In this study CS stimulation but not H.i 
stimulation increased the release of IFNγ. And the combination of CS with ld-H.i 
decreased IFNγ compared to all groups in BALF. 
The role of Th17 cells in both asthma and COPD is largely unknown. However, 
IL-17A level which released by Th17 cells are reported to be increased in the sputum 
of asthma patients. Some studies reported that The Th17 cells were also increased in 
the airways of asthmatic patients (178). IL-17a and IL-17f are related to  
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neutrophil-mediated inflammation. Airway epithelial cells and airway smooth muscle 
cells are able to release CXCL1and CXCL8 which are chemo-attractant for neutrophil 
(179). Therefore, the IL-17A may play a role in the neutrophilic inflammation in 
severe asthma and COPD (180). In this study, the ld-H.i and CS stimulation did not 
induce the expression of IL-17A in the mice lung. However, the combination of 
hd-H.i with additional CS exposure induced a remarkable increase of IL-17a in lung 
homogenate. 
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Fig.3.4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.3.4.1 
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Figure.3.4.1 CS and nebulized H.i stimulation increased the release of pro-inflammatory 
cytokines in BALF.  
Mice were lavaged using protease-inhibitor contained ice-cold PBS 24h after last CS exposure. 
Cytokines were analyzed by CBA or ELISA. A. The release of KC, TNFα, IL-2, IL-4, IL-10, IL-17a 
and IFN-γ in BALF. B. The release of KC, TNFα, IL-1β and MIP-1γ in lung-homogenate. Results are 
means ± SEM, n=5, *p<0,05;  ** p<0,01; ***p<0,001.   
 
 
3.4.2  CS and H.i stimulation at 6 month significantly induced the 
release of IL-17a in BALF. 
 
To understand the inflammatory response of mice after 6 months H.i and CS 
stimulation, the release of TNFα, KC, IFNγ, IL-2, and IL-17a in BALF was analyzed 
using CBA. The stimulation with CS and H.i had no influence on the release of IL-2 
in BALF after 6 month. CS alone decreased the concentration of IFNγ in BALF after  
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6 months compared to 2 weeks, but the combination of hd-H.i and CS significantly 
increased IFNγ in BALF. 
ld-H.i and hd-H.i in CS exposed mice did not significantly change the release of IFNγ 
in BALF. 
The stimulation with ld-H.i and hd-H.i for 6 months significantly increased the release 
of IL-17αinto the BALF. hd-H.i in CS exposed mice significantly increased IL-17α in 
BALF compared hd-H.i alone. 
The release of TNFα in BALF was not increased after 6 months of CS exposure. The 
stimulation with ld-H.i. significantly increased the concentration of TNFα in BALF 
while the combination with CS slightly reduced TNFα concentrations. The further 
increase in microbial stimulation in the hd-H.i. groups caused only a slight increase in 
TNFα-release compared to ld-H.i. alone.  
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Figure.3.4.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.3.4.2. nebulized H.i synergistically stimulated the release of IL-17a in BALF.  
Mice were as described in 2 weeks exposed. The release of IL-2, IFN-γ, IL-17a and TNFα in BALF 
was analyzed by CBA. Results are means ± SEM, n=5, *p<0,05;  ** p<0,01; ***p<0,001.  
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3.5  CS and H.i stimulation induced the expression of MMPs and 
TIMPs in lung-homogenate 
 
Matrix metalloproteinases (MMPs) are believed to play an important role in the 
pathogenesis of emphysema and are believed to be responsible for the destruction of 
alveolar walls and the degradation of connective tissue elements. Therefore we 
systematically analyzed the expression of various MMPs and their inhibitors (TIMPs) 
in CS and H.i exposed mice. The expression of MMP2, MMP9, MMP12, neutrophil 
elastase, TIMP1, and TIMP2 in lung homogenate was analyzed using qRT-PCR.   
 
3.5.1  hd-H.i in CS exposed mice synergistically stimulated the 
expression of MMP12 in lung-homogenate at 2 weeks.  
 
The stimulation with CS and H.i did not affect the expression of MMP2. hd-H.i 
stimulation in CS exposed mice induced the expression of MMP9 and TIMP1. ld-H.i 
and the hd-H.i stimulation decreased the expression of neutrophil elastase. The ld-H.i 
and the hd-H.i in CS exposed mice significantly decreased the expression of TIMP2. 
The mRNA level of MMP12 was determined using qRT-PCR. CS had no influence on 
the expression of MMP12 after 2 weeks exposure. ld-H.i significantly induced the 
expression of MMP12 in lung homogenate compared to air controlled mice and CS 
exposed mice (Fig. 3.5A). ld-H.i stimulation in CS exposed mice decreased the 
expression of MMP12 in lung homogenate. hd-H.i in CS exposed mice increased the 
MMP12 mRNA level up to 120 folds compared air controlled mice. The expression of 
MMP12 in protein level was also confirmed through Western Blot analysis using 
antibody against MMP12. As it is shown in Fig.3-5B hd-H.i stimulation induced 
dominant increase of MMP12 in lung-homogenate. To confirm the localization of 
MMP12 in lung the IHC analysis was performed on paraffin-embedded lung tissue 
(Fig.3.5C). The expression of MMP12 in group of hd-H.i stimulation was detected 
both in airway epithelial cells and in alveolar immune-cells.   
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Figure.3.5.1 
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Figure. 3.5.1 CS and H.i stimulations induced the expression of MMPs and TIMPs in lung 
homogenate after 2 weeks. 
A. The expression of MMPs and TIMPs in lung-homogenate was determined after 2 weeks CS- and H.i. 
exposure using qRT-PCR.  B. The expression of MMP12 under various conditions was determined 
through Western Blot analysis using antibody against MMP12. β-actin was used as loading -control. 
Results are means ± SEM, n=5, *p<0,05;  ** p<0,01; ***p<0,001. C. Immunohistological analysis 
confirmed the expression and the localization of MMP12 in lung tissue. The stimulation of CS, 
ld-H.i, hd-H.i and CS+ld.H.i increased the expression of MMP12 in immune cells while stimulation 
with CS+hd-H.i leads to the accumulation of MMP12 in immune cells and also in epithelial cells. 
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3.5.2  CS and H.i stimulated the expression of MMP9 and TIMP1 in 
lung-homogenate at 6 month. 
 
hd-H.i in CS exposed mice significantly increased the expression of MMP12 in lung 
homogenate compared to air controlled mice at 6 month but not in hd-H.i alone. ld-H.i 
also reduced the expression of MMP12 in CS exposed mice compared ld-H.i alone.  
hd-H.i in CS exposed mice significantly increased the expression of MMP9 in lung 
homogenate compared to air controlled mice and hd-H.i. exposed mice alone.  The 
expression of MMP9 was lower in hd-H.i. exposed mice than in ld-H.i treated 
animals. 
CS and ld-H.i significantly increased the expression of TIMP1 at 6 month compared 
to air controlled mice. hd-H.i also significantly increased the expression of TIMP1 in 
CS exposed mice.  
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Figure.3.5.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 3.5.2 CS and H.i stimulated the expression of MMPs and TIMPs in lung homogenate 
after 6 month. 
Mice were treated as described before for 6 months. The expression of MMP9, MMP12 and TIMP1 in 
lung-homogenate was determined by qRT-PCR. Results are means ± SEM, n=5, *p<0,05;** p<0,01; 
***p<0,001. 
 
 
3.6 CS and H.i stimulation induced the mucus hypersecretion 
To determine whether mucus production was affected following H.i and CS 
stimulation in mice, lung tissues were stained with PAS to analyze mucus-producing 
cells (Fig.3.6.1 A). 
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3.6.1 CS plus hd-H.i stimulation induced more PAS positive cells in 
large airways from 2 week up to 6 month.  
 
Increased mucus hypersecretion by goblet cells of hd-H.i and CS exposed mice were 
observed in this study (Fig 3.6.1). We identify the PAS positive cells from 3 blind 
random selected slices of each mouse in every group. The hd-H.i stimulation plus CS 
exposed mice showed the most dominant effect on the PAS positive cells. 
CS and H.i stimulation for 6 month also increased mucus production by goblet cells. 
hd-H.i in CS exposed mice significantly increased the number of PAS positive cells in 
big airways compared with only CS exposed mice. The groups of CS alone, ld-H.i and 
hd-H.i also increased PAS positive cells.  
The number of PAS positive cells from 2 weeks up to 6 months was quantified and is 
shown in Fig. 3.6.1 A and B. The curve of group CS+hd-H.i was always above all 
other groups from 2 weeks up to 6 months. It confirmed that the combination of CS 
and hd-H.i induced a marked increase of PAS positive cells in big airways compared 
to CS alone or hd-H.i alone exposed mice. And it showed that the numbers of PAS 
positive cells following CS or H.i stimulation were not marked changed with time. 
The PAS positive cells in big airway of different groups in different time point were 
clearly figured out in Fig. 3.6.1C. It showed, that hd-H.i in CS exposed mice induced 
most PAS positive cells in big air way.  
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Figure.3.6.1 
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Figure. 3.6.1 The effect of H.i and CS on mucus secretion from 2 weeks up to 6 month. 
Mice were treated as described before for 2 weeks, 3month and 6 month. Lung tissues were fixed and 
stained with PAS. A. statistical analysis of PAS positive cells in big air way at 2 weeks. B. statistical 
analysis of PAS positive cells in big air way at 6 month. C. PAS staining from 2 weeks to 6 month. 
Results are means ± SEM, n=5, *p<0,05;  ** p<0,01; ***p<0,001. C. PAS staining of Lung tissue. 
Bar = 100 μm.  
 
 
3.7 H.i stimulation induced connective tissue deposition in lungs at 6 
month. 
 
AZAN staining for connective tissue was performed on this study. The connective 
tissue deposition was observed in all groups of H.i stimulated mice. The ld-H.i and  
2 week 3 month 6 month 
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hd-H.i stimulation significantly induced the connective tissue deposition around small 
airway and alveolar wall. hd-H.i in CS exposed mice increased connective tissue 
deposition compared only hd-H.i stimulated mice. But ld-H.i in CS exposed mice 
showed decreased connective tissue deposition in mice lung. This effect was also 
confirmed in lung function. The ld-H.i in CS exposed mice at 6 month showed 
negative effect of vital capacity and Quasi-static compliance compared only ld-H.i 
stimulated mice. 
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Figure. 3.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 3.7 The CS and H.i stimulation induced connective tissue deposition in lung at 6 
month.  
Mice were treated as descripted before for 6 month. Lung tissues were fixed and stained with AZAN. 
Bar = 50 μm. 
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4. Discussion 
 
The main cause of chronic obstructive pulmonary disease in the developed countries 
is cigarette smoke. COPD include systematic inflammation and emphysema led to 
airway inflammation, destruction of airway parenchyma, and elevated protease 
expression (181). Exacerbations of COPD are defined as a periods of acute worsening 
symptoms, resulting to morbidity and mortality. Increased airway and systemic 
inflammation and pulmonary parenchymal remodeling are the main manifestation of 
COPD during exacerbation. It is normally accepted, that COPD exacerbations are 
triggered by respiratory virus, bacterial infection and/or air pollution, which infected 
the lower airway and increase airway inflammation (182). However, the interaction of 
bacterial infection and CS in the exacerbations of COPD, whether frequent 
exacerbations accelerate the progression of emphysema, and the intracellular 
signaling mechanisms activated by tobacco smoke and bacteria such as Haemophilus 
influenzae that mediate the protease/antiprotease imbalance and subsequent matrix 
degradation in the lungs are not well understood.  
In this study we focus on the interaction of CS and H.i in the mouse model, and 
examined the effect of CS on different doses of H.i including the inflammatory 
response, changes in lung function, mucus hypersecretion, MMP12 and TIMP1 
expression, and tissue remodeling. We demonstrate that CS suppresses the 
inflammatory response on ld-H.i exposed mice and enhances the inflammatory 
response on hd-H.i exposed mice, induces the MMP12, TIMP1 and IL-17α expression, 
promotes changes in lung function and tissue remodeling. According to our 
observation of IL-17α expression, MMP12 expression in macrophage and epithelial 
cells we conclude that the interaction of CS and H.i in macrophage and epithelial cells 
play an important role in the pathogenesis of CS and H.i induced inflammation and 
tissue remodeling in lung. 
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4.1 The inflammatory response during CS and H.i stimulation 
 
Expose to cigarette smoke changes lung immunity and induces impaired pulmonary 
function and mucus hypersecretion (183). Haemophilus influenzae (H.i) as an 
opportunistic bacterial pathogen is frequently colonized in upper airway in healthy 
humans. H.i was isolated frequently from acute and chronic respiratory infections 
such as pneumonia, chronic bronchitis and COPD (150, 156). Alveolar macrophages 
are important for the clearance of bacterial infections. However, the interaction of 
alveolar cigarette smoke and pathogens with innate immunity in lung at cellular level 
remains poorly understood.  
As described in introduction, the cellular pattern changes during exacerbations, 
eosinophils and neutrophils are the major components of the inflammatory response 
(170, 171). Patients suffering from chronic bronchitis showed in bronchial biopsies a 
dominant airway eosinophilia up to 30-fold increase of eosinophils, and also lightly 
increased neutrophils, T lymphocytes, and other TNFα–positive cells (184). Other 
study reported that patients with severe chronic bronchitis showed increased 
neutrophils and eosinophils in bronchial alveolar lavage fluid, and the neutrophil is 
more dominant than eosinophils (154). COPD patients during severe exacerbation in 
bronchial biopsies showed increased numbers of neutrophils compared with stable 
COPD patients. However, other cell types in bronchial biopsies were not reported 
(150). 
According to our finding in this study, the additional stimulation with CS in 2 weeks 
ld-H.i exposed mice induces the changes of inflammatory phenotype from 
macrophage based inflammation to neutrophilic inflammation (Figure 3-2B). This 
finding is similar with the changes of cellular pattern during exacerbations in patients 
with COPD. This change is not observed in long term stimulation with CS, for 
example 3 month and 6 month (Figure 3.2, Figure 3.4). And this finding indicates an 
adaptive process in group of CS plus ld-H.i exposed mice. We also observed the 
upregulation of KC and TNFα in BALF of CS plus ld-H.i exposed mice. We 
hypothesize, that this change of inflammatory phenotype may be caused by the KC 
and TNFα induced recruitment of neutrophils in BALF.  
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IL-8 is a chemoattractant for neutrophils and CD8+ T lymphocytes and secreted by 
diverse cell types, including bronchial epithelial cells, macrophages, and neutrophils. 
The expression of IL-8 is upregulated in air space in response to cigarette smoke. 
COPD patients have significantly increased IL-8 level in sputum than healthy smokers 
(19), and the IL-8 level relates to the decline in FEV1 (155). Other studies reported 
that COPD patients during severe exacerbation have increased IL-8 level in both 
sputum and serum, but there are also studies demonstrated that IL-8 was not 
significantly increased at exacerbation. COPD patients with frequent exacerbations 
have also higher sputum IL-8 level (185).  
TNF-α is a proinflammatory cytokine. Alveolar macrophages release most TNF-α in 
lung. TNF-α shows diverse proinflammatory effects, such as neutrophil degranulation, 
respiratory burst and induction of interleukin IL-8 expression. TNF-α is increased in 
the sputum of COPD patients compared with healthy smokers (186) and also in 
COPD patients colonized with H.i (187). TNF-α is further increased in sputum from 
COPD patients during exacerbation compared with stable COPD (183), and also 
during bacterial exacerbations of chronic bronchitis (154). TNF-α recruits and 
activates neutrophils in lung. In total, TNF-α may act as a central mediator of 
neutrophilia in COPD exacerbation. 
Our finding in the mouse model is similar with the expression of IL-8 and TNF-α in 
exacerbation of COPD. Additional stimulation with CS induces significantly 
expressed KC and TNF-α in BALF in hd-H.i exposed mice.  But the significant 
expression of KC and TNF-α in BALF in CS+ld-H.i exposed mice is not observed.  
The molecular mechanisms whereby inflammatory mediators are upregulated at 
exacerbation remain undetermined. It has been reported in some study that the 
transcription factor NF-κB may act as a central role of inflammatory response at 
exacerbation. The transcript activation of nuclear factor NF-κB and activator protein-1 
was also observed in some human bronchial epithelial cell lines which infected with 
rhinovirus (63, 187).  
According to our findings in this study, we also observe the enhanced expression of 
TNF-α in epithelial cells of group of CS+ hd H.i (Data not shown). It suggests that CS 
stimulation in hd-H.i exposed mice induces the enhanced expression of TNF-α in  
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epithelial cells.    
 
 
4.2 The expression of MMPs and TIMPs during CS and H.i stimulation. 
 
The MMPs are a family of Zn binding enzymes for the degradation of most 
extracellular matrix components. We have chosen gelatinase (MMP-2 and MMP-9), 
metalloelastase (MMP-12) and its inhibitors TIMP1 and TIMP2 for the present study. 
All these MMPs have been implicated in the genesis of COPD and are reported to be 
increased in the pulmonary parenchyma of COPD patients (188).  
MMP-12 is released mainly in alveolar macrophages. Recent studies reported the 
detection of MMP-12 in other cell types such as normal human bronchial epithelial 
cells, smooth muscle cells and in various primary brain neoplasms (189-191). In this 
study, the results based on IHC using antibody against MMP12 also indicated the 
expression of MMP12 in both macrophage and epithelial cells in response of CS and 
H.i. We believe that this is the first description of MMP-12 production in lung 
epithelial cells in response of CS and H.i. 
In this study, we have analyzed for the first time the changes of expression level of 
MMP2, MMP9, MMP12, TIMP1 and TIMP2 is related to the exposure of CS and H.i 
in mouse model. ld-H.i and hd-H.i exposure alone induced the expression of MMP12 
at 2 weeks, the combination of hd-H.i and CS synergistically induced the expression 
of MMP12 at 2 weeks but not after 6 month (Fig. 3.8). The MMP12 expression 
induced by the combination of CS and hd-H.i was also confirmed using western blot 
in protein level. In total, the combination of cigarette smoke and H.i induces increases 
in gene expression and protein levels of MMP12 that are potentially important in 
parenchyma remodeling of lungs. 
TIMP proteins are the specific inhibitors of MMPs. Up to now, there are 4 TIMPs 
include TIMP1, TIMP2, TIMP3 and TIMP4 discovered in vertebrates. TIMP-1 
releases mainly from macrophages and fibroblasts suggesting that TIMP-1 is involved  
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in tissue remodeling linking to inflammatory process. The present study indicates that 
MMP-9 and TIMP-1 are elevated in COPD patient during exacerbation. Our findings 
are similar with these studies.  
We were surprised to observe that the TIMP2 was dramatic reduced as a result of 
exposing to CS and H.i. Strong evidence indicates that MMP/TIMP imbalance is an 
import element of the process of tissue remodeling. With regards to our findings, we 
cannot make definitive comments on the balance between MMP and its TIMP. 
 
 
4.3 The possible anti-inflammatory effect of CS in H.i exposed mice. 
 
Cigarette smoke suppresses the innate immune system (192). Increased evidence 
indicated that the cigarette smoke is responsible for many diseases such as heart 
failure, strokes, COPD and cancer (193). Interestingly, smokers have lower risk for 
many diseases, including ulcerative colitis, pigeon breeders’ disease, and Parkinson‘s 
disease (194). As descripted in introduction, the alpha 7 nicotinic receptor pathway 
may play associate with the anti-inflammatory function of nicotine attenuates 
inflammation. The harmful effects are commonly accepted of cigarette smoke. The 
cigarette smoke triggered inflammation is believed as the main risk factor in COPD. 
With regards to our findings, CS exposure at an average concentration of 120 ± 5 
mg/m3 of total suspended particles (TSP) for 3 hours per day lasted 6 month was not 
sufficient to induce a marked inflammatory response in lungs. But the CS in smoke 
box according to 3 days smoke protocol (30 min smoke and break for 15 min, then 
repeat for 5 times per day lasted 3 days) of our lab induced significant infiltration of 
immunocells and increased the neutrophil percentage in mouse lungs (Data not 
shown). CS increased total immunocells infiltration in hd-H.i exposed mice in 2 
weeks, 3 month and 6 month. But CS significantly decreased total immunocells 
infiltration in ld-H.i exposed mice at 6 month (Fig. 3.2). CS inhibited the expression 
of TNFα of ld-H.i exposed mice at 6 month (Fig. 3.4.2). It was also shown in Fig. 
3.4.2 that the CS decreased the connective tissue deposition in ld-H.i exposed mice  
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after 6 month. It indicated that the CS induced anti-inflammatory effect in 1 x/wk H.i 
exposed mice at 6 month.  
Taken together our finding clearly suggests that CS suppresses the inflammatory 
response in ld-H.i exposed mice and enhances the inflammatory response in hd-H.i 
exposed mice. The reason for the effect of CS in different doses of H.i exposed mice 
is unknown. It is possible that CS in ld-H.i exposed mice activates the 7 nicotinic 
receptor pathway suppresses the inflammatory response, then results the decreased 
connective tissue deposition in lung. 
 
 
4.4 The expression of IL-17a  
 
Recent studies reported that IL-17RA deficient mice showed anti-inflammatory 
effects in response to cigarette smoke. And in mice lung was also showed reduced 
transcription activity of MMP12. IL-17RA deficient mice were protected against 
cigarette smoke induced emphysema after 6 months smoke exposure. In total, these 
studies indicated the potential role of TH17 cells in emphysema and COPD.  
Some other studies reported that the IL-17A derived germinal center formation of 
lymphoid follicles in mice and humans lung. Furthermore, the increased TH17 cells 
were observed in COPD patients. In summary, these studies indicated the possible 
role of IL-17A in pulmonary development of lymphoid follicle in COPD patients 
(195). 
In our study the combination of CS and hd-H.i induced the clear expression of IL17A 
at 2 weeks and significant expression at 6 month. The lymphoid follicle development 
is also observed after 3 month and 6 month in CS and H.i exposed mice lung. We 
hypothesize that IL-17a dependent signaling is mainly activated in epithelial cells. 
The CS and H.i exposure activates epithelial cells resulting the lymphoid follicle 
development in mice lung. 
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4.5 Airway and alveolar fibrosis 
 
Airway wall fibrosis is believed to be one of the most common tissue remodeling in 
COPD, and results to the airflow limitation (196) (197). H.i is the most frequently 
isolated pathogen in COPD patients with bacterial exacerbation (159).  In this study, 
repetitive exposure to nebulized lysate of heat inactivated H.i induced progressive 
airway wall fibrosis with a clear increase of collagen deposition around airway wall 
from 3 month was observed in mice lung (Figure 3.7). Some Studies also reported that 
COPD patients have coexisting of alveolar fibrosis with parenchyma destruction 
(198) . This finding indicates that frequent intrapulmonary infection of COPD patients 
by H.i may lead to alveolar fibrosis in lung. For the further treatment, this finding 
implies the consideration of anti- fibrosis therapy for the OPD patients with bacterial 
infection might be undertaken.  
 
 
4.6. Conclusion 
 
Current studies regarding COPD and AECOPD focus on the inflammatory response 
including the proinflammatory mediator such as IL-8, IL-6, IL-1β and TNF-α with 
inflammatory signaling pathway including NF-κB, MAP kinases, STATs and IFN 
regulatory factor 1 (IRF1) (153), which believed to be important for the pathogenesis 
of COPD and exacerbation. There is also various studies focus on functional 
abnormalities in leukocyte of COPD patients. However, there are no studies which 
intensively investigate the interaction of CS and H.i in mice lung. We believe that this 
is the first study to investigate the interaction of CS and H.i related immune and 
structure alteration in mice lung, and firstly demonstrate that CS and H.i induced 
synergetic inflammatory results to impaired lung function. 
According to our findings, we demonstrated that the H.i stimulation induced the 
recruitment of macrophage and neutrophil to the lung, mainly induced the release of  
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inflammatory mediators in immunocells, such as macrophage, neutrophils. Additional 
CS stimulation induced the activation of epithelial cells, and enhanced the 
macrophage recruitment, induced the expression of IL-17a in epithelial cells, and the 
mucus hypersecretion and also induced the expression of MMP12 and TIMP1 not 
only in macrophage but also in epithelial cells (Figure 4.1). The activation of 
epithelial cells depends on the doses of H.i stimulation: CS inhibited the inflammatory 
response of low doses H.i induced inflammation, CS selective enhanced the release of 
inflammatory mediators in epithelial cells in high doses H.i exposed mice, and 
resulted impaired lung function and tissue remodeling. Firstly, our studies establish a 
new mouse model for the study of COPD with bacterial infection. Our findings 
highlight the targets of the interaction of combined CS and H.i simulation in mice 
lung and provide with a new insight for the therapy of COPD patients with bacterial 
infection. 
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Figure.4.1 
 
 
Figure. 4.1. The novel aspect of the interaction of CS and H.i in exacerbation of COPD 
H.i induces the immunocells recruitment in lung and induces the release of proinflammatory mediators 
such as KC, TNF-α. Additional CS stimulation induces the activation of epithelial cells and induces the 
expression of MMP12 and IL-17A in epithelial cells, enhances the recruitment of immunocells in lung, 
results the changes in lung function and enhanced tissue remodeling in lung. 
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